The Lancet. OncologyAdultAgedFemaleHumansMale
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Lanyi N Chen, Francesca R Ogliari, Paul Stockhammer, Rajat Thawani, Shahm Raslan, Eleonora Gariazzo, Francesca Fusco, Grace M Hambelton, Fabrizio Citarella, David Meyer
Published: 202510.1016/S1470-2045(25)00409-7
Abstract
BACKGROUND: Patients with BRAFV600E (ie, Val600Glu)-mutated non-small-cell lung cancer (NSCLC) can be treated with BRAF and mitogen-activated protein kinase (MEK) inhibitors, or with immune checkpoint inhibitors (ICIs) with or without chemotherapy. W…
Preview only. Read the full abstract at the source